Already have an ACS ID? Log in
Renew your membership, and continue to enjoy these benefits.
Already an ACS Member? Log in here
Choose the membership that is right for you. Discount will be applied automatically at checkout.
Enjoy these benefits no matter which membership you pick.
Most Popular in Business
Eli Lilly & Co. has licensed worldwide rights to a small-molecule transcriptional regulator for the treatment of osteoarthritis to Transition Therapeutics. Toronto-based Transition says the drug, TT-601, has completed preclinical development and can enter the clinic next year. Under the agreement, Lilly has an option to reacquire rights to TT-601 after reviewing clinical results. The two firms struck a similar deal over TT-401, a diabetes drug candidate, in 2010. Last month Lilly exercised its option to reacquire that drug.
This article has been sent to the following recipient: